Article | February 7, 2024

Adopting Modular, Semi-Automated Approaches To Optimize Process And Analytical Development For Cell & Gene Therapies

By Rubina Pal and Alicia Kramer, Comprehensive Cell Solutions

GettyImages-1327112218 Scientist using a laptop in a laboratory

The complexities inherent in today’s biopharmaceutical development paradigm have necessitated novel approaches for early phase workflows that can accelerate timelines and reduce cost and risk. For both process and analytical development (PD and AD) in the advanced therapy space, this drive toward more automated, closed processing has led to unprecedented innovation aimed at standardizing these workflows to the same degree as other, more incumbent therapeutic modalities.

Yet this pursuit of fully automated, completely closed PD and AD can serve to create new challenges for a workflow – going “all in” on a platform has the potential to introduce inflexibility, limit scalability, and complicate tech transfer. This is largely due to the diversity and complexity of the CGT products in the current development pipeline, which often require customized approaches and bespoke solutions to address the unique variables that accompany their optimization.

There are a number of technology solutions that, when applied to a cell and gene therapy workflow, can streamline development and improve workflow integration. By pursuing targeted automation and modularity for a program, developers can eliminate common workflow bottlenecks, improve manufacturing reproducibility, and establish a highly flexible and controlled development paradigm that can adapt to technical and business considerations.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises